ArticleESMO gastrointestinal oncology2025
Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.
Y Suzuki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.